window.dataLayer = window.dataLayer || []; function gtag(){dataLayer.push(arguments);} gtag('js', new Date()); gtag('config', 'G-4PR1PSYQLJ'); Skip to content

Welcome to Discover Pharma! Today is : April 15, 2026

  • News
  • Featured News Archives
    • 12 Days of Christmas
    • Women in Pharma
  • About Us
Contact Us

obesity treatment

  • Obesity,Pharmaceuticals and therapeutics,Research & Development

    Currax highlights peer-reviewed review supporting combination approaches in obesity treatment

    Currax Pharmaceuticals is highlighting a peer-reviewed publication supporting the use [...]

    April 10, 2026
  • Artificial Intelligence,Clinical Development,Genomics and sequencing,Obesity,Precision medicine,Technology and platforms

    23andMe study links genetics to GLP-1 weight loss outcomes and side effects

    This Nature-published study from the 23andMe Research Institute identifies genetic [...]

    April 9, 2026
  • Biotech,Drug Delivery & Formulation,Obesity,Pharmaceuticals and therapeutics,Research & Development,Supply Chain & Logistics,Technology and platforms

    Nanexa looks to get under the skin of GLP-1s and beyond

    Nanexa says its long-acting subcutaneous technology could reduce the dosing [...]

    November 4, 2025
  • Medical devices

    Morphic Medical appoints Jane Wright as chief financial officer during European rollout of Reset

    Appointment strengthens leadership team as company expands access to its [...]

    September 15, 2025
  • Chronic diseases,Clinical Trials,Drug Development,Pharmaceuticals and therapeutics

    Skye completes 26-week CBeyond study of nimacimab and eyes 52-week weight loss data

    Skye Bioscience has reached a key milestone in its CBeyond [...]

    September 8, 2025
  • Digital Health,Drug Development,Global health,Market Access & Commercialization,Patient Centricity,Real world evidence,Women's Health

    Patient voices take centre stage as Currax leans into authenticity in obesity care

    As debate continues over the cost and sustainability of GLP-1 [...]

    August 5, 2025
  • Clinical Development,Drug Delivery & Formulation,Drug Development,Medical devices,Regulatory Affairs

    MHRA approval expected soon for non-surgical weight loss device RESET

    Morphic Medical’s non-invasive weight loss device RESET is expected to [...]

    July 18, 2025
  • Biologics & Biosimilars,Clinical Trials,Drug Development,Patient Centricity

    Ciloa lands €6.5 million (£5.7 million) government backing to develop novel obesity and diabetes bio-drug

    Ciloa, a pioneer in bioengineering extracellular vesicles (EVs) for innovative [...]

    July 8, 2025

Bringing you the latest industry news and insights every day

Registered Address: Discover Pharma Ltd, 1 Dartmouth Close, Brighton, BN2 4HZ, UK
Company Number: 16239596

  • About Us
  • Contact Us
  • Legal
    • Cookie Policy
    • Privacy Policy
    • Terms & Conditions
  • Author Guidelines
    • Pharmaceutical Author Guidelines
    • Press Release Advice
  • Advertise with Us
  • Media Kit Request

© 2026 Discover Pharma. All rights reserved • Developed by Hairy Goat Design

Page load link

Press “ESC” key to close

main menu
  • Home
  • News
  • About Us
  • Contact
recent posts
  • ProQR partners with Ginkgo Bioworks for AI-driven RNA editing development and forms advisory board
    Categories: Artificial Intelligence, Biotech, Drug Development, Drug discovery, Research & Development
  • Weite Oldenziel
    Ofichem unifies CDMO and pharmaceutical supply brands under single identity
    Categories: CDMOs & Manufacturing, Supply Chain & Logistics
  • DeepCyte raises $1.5M to advance single-cell AI toxicology platform for drug development
    Categories: Artificial Intelligence, Drug discovery, Funding, Technology and platforms
get connected
This website uses cookies and third party services. See our Cookie Policy and Privacy Policy pages for details. OK
Go to Top